BRIEF-Travere Therapeutics Says FDA Extends Review Of SNDA For Filspari (Sparsentan) In FSGS

Reuters01-14

BRIEF-Travere <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Says FDA Extends Review Of SNDA For Filspari (Sparsentan) In FSGS

Jan 13 (Reuters) - Travere Therapeutics Inc TVTX.O:

TRAVERE THERAPEUTICS ANNOUNCES FDA EXTENDS REVIEW OF SNDA FOR FILSPARI® (SPARSENTAN) IN FSGS
TRAVERE THERAPEUTICS INC - NEW PDUFA TARGET ACTION DATE SET FOR APRIL 13, 2026
TRAVERE THERAPEUTICS INC - NO ADDITIONAL SAFETY OR MANUFACTURING INFO REQUESTED FOR FILSPARI

Source text: ID:nBw3C8WsLa

Further company coverage: TVTX.O

((Reuters.Briefs@thomsonreuters.com;;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603404634?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-14 02:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603404634","market":"fut","top_or_hot":-1,"title":"BRIEF-Travere Therapeutics Says FDA Extends Review Of SNDA For Filspari (Sparsentan) In FSGS","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Travere <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Says FDA Extends Review Of SNDA For Filspari (Sparsentan) In FSGS</title></head><body><p><span>Jan 13 (Reuters)</span><span> - </span>Travere Therapeutics Inc <span>TVTX.O</span>:</p><ul><li><p>TRAVERE THERAPEUTICS ANNOUNCES FDA EXTENDS REVIEW OF SNDA FOR FILSPARI® (SPARSENTAN) IN FSGS</p></li><li><p>TRAVERE THERAPEUTICS INC - NEW PDUFA TARGET ACTION DATE SET FOR APRIL 13, 2026</p></li><li><p>TRAVERE THERAPEUTICS INC - NO ADDITIONAL SAFETY OR MANUFACTURING INFO REQUESTED FOR FILSPARI</p></li></ul><p>Source text: <span>ID:nBw3C8WsLa</span></p><p>Further company coverage: <span>TVTX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Travere Therapeutics Says FDA Extends Review Of SNDA For Filspari (Sparsentan) In FSGS</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Travere Therapeutics Says FDA Extends Review Of SNDA For Filspari (Sparsentan) In FSGS\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-14 02:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Travere <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Says FDA Extends Review Of SNDA For Filspari (Sparsentan) In FSGS</title></head><body><p><span>Jan 13 (Reuters)</span><span> - </span>Travere Therapeutics Inc <span>TVTX.O</span>:</p><ul><li><p>TRAVERE THERAPEUTICS ANNOUNCES FDA EXTENDS REVIEW OF SNDA FOR FILSPARI® (SPARSENTAN) IN FSGS</p></li><li><p>TRAVERE THERAPEUTICS INC - NEW PDUFA TARGET ACTION DATE SET FOR APRIL 13, 2026</p></li><li><p>TRAVERE THERAPEUTICS INC - NO ADDITIONAL SAFETY OR MANUFACTURING INFO REQUESTED FOR FILSPARI</p></li></ul><p>Source text: <span>ID:nBw3C8WsLa</span></p><p>Further company coverage: <span>TVTX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TVTX","symbol_name":"Travere Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUA5F8M7H:1","article_id":"2603404634","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603404634","pubTimestamp":1768328789,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Travere Therapeutics Says FDA Extends Review Of SNDA For Filspari (Sparsentan) In FSGSJan 13 (Reuters) - Travere Therapeutics Inc TVTX.O:TRAVERE THERAPEUTICS ANNOUNCES FDA EXTENDS REVIEW OF SNDA","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TVTX":"Travere Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"简介-Travere Therapeutics表示FDA延长了FSGS中Filspari(Sparsentan)SNDA的审查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TVTX":0.9},"content_text":"BRIEF-Travere Therapeutics Says FDA Extends Review Of SNDA For Filspari (Sparsentan) In FSGSJan 13 (Reuters) - Travere Therapeutics Inc TVTX.O:TRAVERE THERAPEUTICS ANNOUNCES FDA EXTENDS REVIEW OF SNDA FOR FILSPARI® (SPARSENTAN) IN FSGSTRAVERE THERAPEUTICS INC - NEW PDUFA TARGET ACTION DATE SET FOR APRIL 13, 2026TRAVERE THERAPEUTICS INC - NO ADDITIONAL SAFETY OR MANUFACTURING INFO REQUESTED FOR FILSPARISource text: ID:nBw3C8WsLaFurther company coverage: TVTX.O ((Reuters.Briefs@thomsonreuters.com;;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603404634","isCrawlerRequest":true}